Skip to content
ETopical – Lifestyle
Home
Sample Page
Author:
ConSynance Therapeutics
ConSynance Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of CSTI-500 for Prader-Willi Syndrome
June 16, 2026